These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21800195)

  • 1. [Prevention of bone loss in a patient receiving androgen deprivation therapy].
    Rolfes N; Lümmen G
    Urologe A; 2011 Nov; 50(11):1383-6. PubMed ID: 21800195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
    Smith MR; Egerdie B; Hernández Toriz N; Feldman R; Tammela TL; Saad F; Heracek J; Szwedowski M; Ke C; Kupic A; Leder BZ; Goessl C;
    N Engl J Med; 2009 Aug; 361(8):745-55. PubMed ID: 19671656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
    Kudlacek S; Puntus T
    Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation in prostate cancer and the long-term risk of fracture.
    Ojeda S; Lloret M; Naranjo A; Déniz F; Chesa N; Domínguez C; Lara PC
    Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW; Small EJ
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer and osteoporosis.
    Tuck SP; Hanusch B; Walker J; Datta HK
    Curr Osteoporos Rep; 2013 Mar; 11(1):11-20. PubMed ID: 23355097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical guide to the management of osteoporosis in men with prostate cancer receiving androgen-deprivation therapy.
    Bruder JM
    Curr Urol Rep; 2005 May; 6(3):157-8. PubMed ID: 15869718
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prevention of osteoporosis--important for the urologist?].
    Lümmen G; Rübben H; Schneider T; Sperling H
    Urologe A; 2007 Jun; 46(6):651-5. PubMed ID: 17453170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
    Spanjol J; Maricić A; Valencić M; Oguić R; Krpina K; Protić A; Ivancić A; Bobinac M; Fuckar D; Vojniković B
    Coll Antropol; 2008 Oct; 32 Suppl 2():79-81. PubMed ID: 19138011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR
    Drugs Aging; 2003; 20(3):175-83. PubMed ID: 12578398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer: Bone density testing--essential or extraneous?
    Yu EY
    Nat Rev Urol; 2013 Jan; 10(1):11-2. PubMed ID: 23229500
    [No Abstract]   [Full Text] [Related]  

  • 12. Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer.
    Saylor PJ
    Asian J Androl; 2014; 16(3):341-7. PubMed ID: 24435057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Tomlinson GA; Winquist E
    Ann Intern Med; 2017 Sep; 167(5):341-350. PubMed ID: 28785760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
    J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
    [No Abstract]   [Full Text] [Related]  

  • 15. Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
    Joseph JS; Lam V; Patel MI
    Eur Urol Oncol; 2019 Sep; 2(5):551-561. PubMed ID: 31411986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of metastatic bone disease and treatment-induced osteoporosis in prostate cancer. Evolution of osteoprotective strategies].
    Todenhöfer T; Schwentner C; Schilling D; Gakis G; Stenzl A
    Urologe A; 2011 Sep; 50(9):1055-63. PubMed ID: 21744161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
    Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence?
    Reddy SV; Gupta SK
    Singapore Med J; 2012 Mar; 53(3):e52-4. PubMed ID: 22434305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of bone loss due to endocrine therapy during cancer treatment.
    Khan MI
    Osteoporos Int; 2023 Apr; 34(4):671-680. PubMed ID: 36656338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of osteoporosis in men on androgen deprivation therapy.
    Adler RA
    Maturitas; 2011 Feb; 68(2):143-7. PubMed ID: 21129866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.